Research across Cancer
Related studies from across the Cancer family.
Follicular T cell subsets and tertiary lymphoid structures may guide immunotherapy in ovarian cancer
New immune targets offer hope for ovarian cancer patients
This narrative review synthesizes evidence on follicular T cell subsets, tertiary lymphoid structures, and other immune features in ovarian …
A review highlights new immune system features that could help doctors predict treatment success and find better ways to fight ovarian cance…
Case report of YL205 antibody-drug conjugate in platinum-resistant ovarian carcinoma
First patient achieves complete response with new ovarian cancer drug YL205
This is a single-patient case report of a 40-year-old woman with platinum-resistant, BRCA-wildtype high-grade serous ovarian carcinoma treat…
A single patient with advanced ovarian cancer achieved a complete response after 24 weeks of treatment with YL205, a new antibody-drug conju…
Case report review of fertility-sparing surgery for ovarian borderline mucinous tumor with carcinosarcomatous mural nodule
A rare ovarian tumor diagnosis explained in a single patient case
This source is a case report review describing a 27-year-old female patient with an ovarian borderline mucinous tumor and carcinosarcomatous…
Doctors treated a 27-year-old woman with a rare ovarian tumor using fertility-sparing surgery and chemotherapy, with no signs of the cancer …
Relacorilant plus nab-paclitaxel improves overall survival in platinum-resistant ovarian cancer
New Drug Combo Extends Survival for Tough Ovarian Cancer Cases
In a phase 3 randomised controlled trial of 381 patients with platinum-resistant ovarian cancer, relacorilant plus nab-paclitaxel significan…
This combination offers a new, simpler option for patients who have run out of standard treatments.
Residual disease after surgery linked to survival in low-grade serous ovarian cancer
For This Ovarian Cancer, Surgery Is Everything—Chemo May Not Help
This observational retrospective study of 25 patients with low-grade serous ovarian cancer found that residual disease status after primary …
For a rare ovarian cancer, a new study suggests that the quality of surgery is the single most important factor for survival, challenging th…
STAT1 and IL-7 show diagnostic potential for ovarian carcinoma subtypes in cohort study
Two Tiny Signals Could Help Doctors Tell Apart Two Ovarian Cancers
A cohort study analyzed transcriptome data from 68 patients with high-grade and low-grade serous ovarian carcinoma.
Two tiny gene signals may help doctors distinguish between two ovarian cancer types when biopsy results are unclear, guiding the right treat…
Precision oncology enables targeted therapies for gynecologic cancers, though acquired resistance remains a barrier
Precision oncology advances gynecologic cancer care but resistance remains a major barrier
This systematic review examined the current landscape of precision oncology for patients with endometrial, ovarian, and cervical carcinomas.
Molecular reclassification lets doctors use targeted drugs effectively for gynecologic cancers, but tumor evolution creates a major barrier …
Chemotherapy in HGSOC patients modulates NK cell receptors and ligands, observational study finds
Chemotherapy linked to immune system changes in ovarian cancer patients
An observational cohort study of 107 HGSOC patients and 50 healthy controls found chemotherapy was associated with modulation of NK cell rec…
Chemotherapy in ovarian cancer may restore natural killer cell markers to healthy levels and boost proteins that help immune cells fight tum…
vNOTES shows non-inferiority to laparoscopy for ovarian cystectomy in pilot trial
Can a gentler surgery remove ovarian cysts with less pain?
A pilot RCT of 64 patients with benign ovarian tumors compared vNOTES to conventional laparoscopy.
A gentler surgery that removes ovarian cysts through the vagina instead of the belly caused less pain after the operation, a small trial fou…